Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz International GmbH

www.sandoz.com

Latest From Sandoz International GmbH

ANI Picks Up US Dermatology Brands From Sandoz

ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.

Deals Strategy

Stockwatch: The Complex Biologics Market Is…Complex

The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.

Stockwatch Biosimilars

Sandoz Aims To Be ‘First In And Last Out’ In North America

Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.

Strategy Leadership

Sandoz Strikes $500m Deal For GSK Cephalosporins

Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.

Deals Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register